

Neurofilament light protein as a blood biomarker for Huntington's disease in children

Lauren M Byrne^{1*†}, Jordan L Schultz^{2†}, Filipe B Rodrigues¹, Ellen van der Plas², Douglas Langbehn², Peg Nopoulos^{2††}, Edward J Wild^{1*††}

Affiliations:

1. Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG
2. Department of Psychiatry, Carver College of Medicine at the University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242

[†] These authors contributed equally as first authors of this study.

^{††} These authors contributed equally as senior authors of this study

* Corresponding authors: lauren.byrne.14@ucl.ac.uk; e.wild@ucl.ac.uk;

Current main text Word count: 18003

Abstract

Juvenile-onset Huntington's disease (JoHD) is a rare, particularly devastating form of Huntington's Disease (HD) for which clinical diagnosis is challenging and robust outcome measures are lacking. Neurofilament light protein (NfL) in plasma has emerged as a prognostic biomarker for adult-onset HD. We report that plasma NfL is elevated in JoHD and premanifest HD mutation-carrying children. Quantifying plasma NfL may improve clinical diagnosis and therapeutic trial design in the pediatric population.

Main text

Juvenile-onset HD (JoHD) is a devastating form of Huntington's Disease (HD) that manifests before the age of 21¹. While the underlying pathology of CAG repeat expansions in *HTT* exon 1 is similar to adult-onset HD (AoHD), JoHD has typically much larger expansions. JoHD has unique disease features including prominent rigidity, dystonia, and bradykinesia, and tends to progress rapidly. There are no disease-modifying therapies for HD but numerous targeted therapeutics are in advanced trials². JoHD is ultra-rare (approximately 5 per million³), contributing to a lack of robust clinical scales or biomarkers that could facilitate clinical trials in this population. Further, initial manifestations of JoHD often overlap with normal variability in childhood or adolescence, or with prevalent juvenile disorders such as depression, anxiety, ADHD, Tourette's syndrome, complicating difficult decisions about diagnosis and genetic testing of minors¹.

Similar to other neurological diseases, plasma neurofilament light chain protein (NfL) has emerged as a biomarker for AoHD that strongly correlates with clinical, cognitive and MRI measures⁴. Baseline plasma NfL concentration increases early and predicts subsequent HD progression and brain atrophy⁴⁻⁷. In a cohort of young adult premanifest HD (preHD) mutation carriers, on average 24 years from estimated onset, NfL concentrations in CSF and plasma were the earliest detectable alterations in HD⁸.

Despite being a robust biomarker for AoHD⁴⁻⁷, NfL has yet to be evaluated in JoHD or in children and adolescent HD mutation carriers who will develop HD in adulthood but

have no disease manifestations (preHD). We quantified plasma NfL in a unique cohort of 9 JoHD subjects, 30 preHD and 61 mutation-free control children and adolescents.

Characteristics of the age-matched cohort are in Supplementary Table 1. We assessed potential confounding demographics (age: Extended Data Fig. 1a; parental socioeconomic status: Extended Data Fig. 1b; sex: Extended Data Fig. 1c; Tanner stage [puberty classification system]: Extended Data Fig. 1d), finding little evidence for the impact of healthy development on plasma NfL concentrations.

We investigated whether plasma NfL was elevated in JoHD. JoHD patients had significantly higher plasma NfL than controls (32.46 pg/mL, [95% Confidence interval (95%CI) 18.08 – 58.27], versus 4.76 pg/mL, [95%CI 4.33 – 5.23] respectively; $p < 0.0001$; Fig. 1a). In JoHD, plasma NfL rose with age on a trajectory significantly distinct from controls (Age*Group: 1.09 pg/mL/year [Confidence interval (95%CI) 1.02-1.16], $p = 0.013$; Fig. 1b). A cutoff of 11.1 pg/mg identified 91% of JoHD cases and 96% of controls (AUC 0.96; Fig. 1c). We also evaluated the relationship between plasma NfL and JoHD clinical measures (Supplementary Table 2). There were no associations between plasma NfL and UHDRS total motor scale, the JoHD Motor scale, or its components, with the exception of the Bradykinesia Drinking measure which had a positive association with plasma NfL (LMER Est. 1.25, [95%CI 0.46 – 2.05] $p = 0.017$). However, this did not survive multiple comparisons correction (false discovery rate $p = 0.103$). There was a significant, positive association between disease duration and plasma NfL concentration (LMER Est. 2.18 [95%CI 0.31 – 4.05] $p = 0.045$). No significant

associations were found between plasma NfL and disease burden score (DBS) or brain volumes in JoHD.

Next, we investigated plasma NfL in preHD children. Overall, the age trajectories of NfL in preHD compared to healthy controls were not statistically different from one another (Age*group: 1.02 pg/mL/year [95%CI 0.97-1.06], $p=0.534$; Fig. 1d). We subdivided preHD by their predicted years to onset (YTO) to assess whether plasma NfL was elevated in children closer to their predicted onset. The characteristics of the YTO groupings are presented in Supplementary Table 3. The mean plasma NfL concentration in controls was 4.76 pg/mL, (95%CI 4.33 – 5.23), which did not differ significantly from preHD 40-60 YTO (5.21 pg/mL, [95%CI 3.96 – 6.84]), 30-40 YTO (4.53 pg/mL, [95%CI 3.45 – 5.94]), or 20-30 YTO (4.10 pg/mL, [95%CI 3.32 – 5.05]). However, the preHD groups that were 15-20 years from onset (7.03 pg/mL [95%CI 5.34 – 9.25]) and within 15 years from predicted onset (10.07 pg/mL [95%CI 7.51 – 13.52]) both had significantly higher plasma NfL than controls ($t=3.31$, $p_{FDR}=0.0033$ and $t=3.72$, $p_{FDR}=0.0015$, respectively; Fig. 1e).

In a combined group of HD mutation carriers (preHD+JOHD), we explored the relationship between plasma NfL and brain volume, including whole brain, caudate and putamen volume, which are of primary pathological importance in HD. There were significant negative associations (Supplementary Table 4; Fig. 1f-h) between plasma NfL and whole-brain (LMER Est. -0.90 [CI -1.64 – -0.16] $p=0.020$; Fig. 1f), caudate (LMER Est. -0.06 [95%CI -0.08 – -0.03] $p=0.0001$; Fig. 1g) and putamen volumes

100 (LMER Est. -0.09 [95%CI -0.12 – -0.06] $p < 0.0001$; Fig. 1h). When exploring at the
 101 associations limiting the analysis to JoHD and preHD children within 20 years from
 102 predicted motor onset, the respective slopes of these associations were greater but,
 103 given the reduced sample size, only caudate (LMER Est. -0.12 [95%CI -0.18 – -0.05]
 104 $p = 0.0040$; Fig. 1g) and putamen (LMER Est. -0.14 [95%CI -0.21 – -0.07] $p = 0.0025$; Fig.
 105 1h) volumes remained significant (Supplementary Table 4).




Fig. 1 Plasma NfL in JoHD and children at-risk for HD.

a, Plasma NfL groupwise differences and **b**, modelled plasma NfL trajectories with age in JoHD compared to controls. **c**, Receiver operating characteristic curve for Plasma NfL discriminating JoHD from controls. **d**, modelled plasma NfL trajectories with age in preHD and **e**, YTO groupwise plasma NfL differences compared to control children. Plasma NfL associations with **f**, whole brain **g**, caudate and **h**, putamen volumes in all HD mutation carriers or those with JoHD and within 20 YTO. Data points are raw plasma NfL. Statistics were generated from LMER models with effects per participant and per family (intercepts) and using Satterthwaite approximation for degrees of freedom. P values in **e** are adjusted for multiple comparisons. For **f-h**, all brain volumes were %ICV; models additionally included a covariate to account for different scanners; and model statistics are presented in Supplementary Table 4. NfL, neurofilament light protein; JoHD, Juvenile-onset Huntington's disease; preHD, premanifest HD; YTO, years to onset; ICV, intracranial volume; LMER, linear mixed effects regression; MD, mean difference.

119 We combined the KidsHD and KidsJoHD cohorts with HD-CSF – a longitudinal cohort of
120 80 adult HD mutation carriers and controls – to compare the course of plasma NfL
121 throughout life in health, JoHD and adult-onset Huntington’s disease (Fig. 2a). Plasma
122 NfL initially begins to rise from approximately DBS 200.




Fig. 2 Plasma NfL throughout the HD mutation carrier lifespan.

Plasma NfL plotted against a. age and b. disease burden score in both the Kids cohort and HD-CSF cohort. Data points are raw plasma NfL. NfL, neurofilament light protein.

The elevation and distinct age trajectory of plasma NfL in JoHD patients compared to healthy control children are consistent with those observed in adult onset HD^{4,6,7}. Associations with clinical measures were modest, although this may be driven by lack of power and limitations in JoHD clinical measures. Furthermore, as previously reported in AoHD⁴⁻⁷, plasma NfL was inversely associated with brain volumes in children with HD mutations, whether JoHD or preHD. Plasma NfL elevation in preHD children within 20 years from predicted onset is consistent with increases reported in a young adult HD cohort. Morphological neurodevelopment differences in the striatum⁹ may limit the utility of MRI to distinguish between the neurodevelopmental and neurodegeneration effects of the HD mutation. NfL could provide insights into the point where neurodevelopment is the predominant concern, potentially helping to inform decisions around the timing of disease-modifying interventions. Collectively, these findings suggest two potential applications of NfL: 1) identification of high-risk children for early diagnosis and intervention; and 2) assessing neuroprotection in cohorts of all ages. By evaluating NfL across a wide age range, we can begin to estimate plasma NfL thresholds indicative of neurodegeneration. This could be of value in informing ethically-challenging decisions about which at-risk children showing possible disease manifestations should undergo genetic testing. We conclude that plasma NfL shows promise as a blood biomarker of JoHD and may facilitate clinical trial design in this rare and understudied population.

References

1. Oosterloo, M., Bijlsma, E. K., de Die-Smulders, C. & Roos, R. A. C. Diagnosing Juvenile Huntington's Disease: An Explorative Study among Caregivers of Affected Children. *Brain Sci.* **10**, 155 (2020).
2. Tabrizi, S. J., Flower, M. D., Ross, C. A. & Wild, E. J. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. *Nature Reviews Neurology* vol. 16 529–546 (2020).
3. Quarrell, O., O'Donovan, K. L., Bandmann, O. & Strong, M. The prevalence of juvenile Huntington's disease: A review of the literature and meta-analysis. *PLoS Currents* vol. 4 (2012).
4. Byrne, L. M. *et al.* Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. *Lancet Neurol.* **16**, 601–9 (2017).
5. Johnson, E. B. *et al.* Neurofilament light protein in blood predicts regional atrophy in Huntington disease. *Neurology* **90**, e717–e723 (2018).
6. Byrne, L. M. *et al.* Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. *Sci. Transl. Med.* **10**, eaat7108 (2018).
7. Rodrigues, F. B. *et al.* Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. *Sci. Transl. Med.* **12**, 2888 (2020).
8. Scahill, R. I. *et al.* Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. *Lancet Neurol.* **19**, 502–512 (2020).
9. van der Plas, E. *et al.* Abnormal brain development in child and adolescent

carriers of mutant huntingtin. *Neurology* **93**, E1021–E1030 (2019).

10. Tereshchenko, A. *et al.* Brain structure in juvenile-onset Huntington disease. *Neurology* **92**, E1939–E1947 (2019).

11. Byrne, L. M. *et al.* Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease. *Sci. Rep.* **8**, 4260 (2018).

12. Lowe, A. J. *et al.* Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease. *PLoS One* **15**, (2020).


13. Horton, M. C. *et al.* Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntington’s Disease. *J. Huntingtons. Dis.* **8**, 181–193 (2019).

14. Penney, J. B., Vonsattel, J.-P., Macdonald, M. E., Gusella, J. F. & Myers, R. H. CAG repeat number governs the development rate of pathology in Huntington’s disease. *Ann. Neurol.* **41**, 689–692 (1997).

15. Langbehn, D., Brinkman, R., Falush, D., Paulsen, J. & Hayden, M. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. *Clin. Genet.* **65**, 267–277 (2004).

16. Khalil, M. *et al.* Serum neurofilament light levels in normal aging and their association with morphologic brain changes. *Nat. Commun.* **11**, 1–9 (2020).

Extended Data



Extended Data Fig. 1 Plasma NfL in healthy development and potential confounding demographics.

Plasma NfL concentrations are plotted against **a**, age **b**, parental socioeconomic status **c**, sex and **d**, Tanner stage (puberty) in healthy control individuals (n=61). Data was available from multiple timepoints for some individuals (83 observations). P-values were generated from linear mixed effects regression models with a random participant effect (intercept). Pairwise tests were post-hoc t-tests using Satterthwaite's method. Raw NfL values are presented. Models used natural log transformed NfL data and was back-transformed for **a**, the age model. NfL, neurofilament light protein; LMER, linear mixed effects regression.

Acknowledgements

We would like to thank all the participants who took part, providing their time, data and samples to make this work possible.

Funding

This work was supported by the Medical Research Council UK (to EJW), the CHDI Foundation (to EJW), the Huntington's Disease Society of America (to LMB), the Hereditary Disease Foundation (to LMB), and the National Institute of Health (NIH) grant NS094387 Growth and Development of the Striatum in Huntington's Disease (to PN).

Author Contributions

EJW, PN, LMB, JLS and DL were responsible the conception and design of the work; LMB, JLS, FBR and EVP were involved in the acquisition of data; LMB and JLS performed the data analysis; EJW, PN, LMB, JLS and DL were involved in the interpretation of data; LMB drafted the first manuscript draft with JLS and incorporated coauthor revisions. All authors approved the submitted version of the manuscript

Competing Interests statement

LMB, FBR and EJW are full-time UCL employees. LMB receives salary support from the Huntington's disease Society of America, and has provided consultancy for F. Hoffmann-La Roche AG, Genentech, Novartis International AG, Annexon Inc and GLG. JLS receives salary support from the National Center for Advancing Translational Sciences (NIH KL2TR002536) and the Michael J. Fox Foundation for Parkinson's Research. FBR receives salary support from CHDI Foundation, and has provided

consultancy to GLG and Roche. E.J.W. reports grants from Medical Research Council UK, CHDI Foundation, and F. Hoffmann–La Roche Ltd. during the conduct of the study and personal fees from F. Hoffman–La Roche Ltd., Triplet Therapeutics, PTC Therapeutics, Shire Therapeutics, Wave Life Sciences, Mitoconix, Takeda Pharmaceuticals Ltd., and Loqus23. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. University College London Hospitals NHS Foundation Trust has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer, and Teva Pharmaceuticals. and Stroke, the CHDI Foundation, University College of London, and from the Wellcome Trust. During the past 12 months, he has served as a paid statistical consultant for the design of Huntington’s Disease trials for Novartis AG, Voyager Therapeutics, Spark therapeutics, and Takeda Pharmaceutical Company Limited. He has also been a paid consultant to Trinity Life Sciences. PN and EVP report no competing interests.

Online methods

Study design

This retrospective analysis involved quantification of plasma NfL using available blood samples and matching phenotypic data that were collected as part of the KidsHD and KidsJoHD studies – observational studies at the University of Iowa that recruited children and young adults with a family history of HD or with Juvenile Onset HD respectively; as well as healthy control volunteers with no known family history of HD. Recruitment began in May 2009 and was completed in January 2018. All KidsHD/JoHD participants provided either saliva or blood for genetic testing which was for research purposes only; results were not revealed to participants, their families, clinicians, or researchers. Both studies implemented an accelerated longitudinal design where some participants attended multiple visits at 1-2 year intervals and so had repeated measures as previously described^{9,10}. The Institutional Review Board at the University of Iowa approved the KidsHD and KidsJoHD studies. The parents or guardians of participants who were less than 18 years old provided written consent and the children provided written assent. Participants who were 18 years or older provided written consent. We combined plasma NfL data from both KidsHD and KidsJoHD with previously published plasma NfL data from the longitudinal HD-CSF cohort to visually assess how NfL fluctuates over the lifespan of the HD mutation carrier. HD-CSF has been extensively described^{6,11,12} (online protocol: DOI: 10.5522/04/11828448.v1).

Participants

For the current analysis, at-risk participants from Kids-HD were classified as premanifest HD (preHD) mutation carriers if their CAG repeat length was ≥ 36 and healthy controls if <36 . JoHD was defined as a UHDRS Total Motor Score ≥ 10 before the age of 21 in the context of the HD mutation and a confirmed diagnosis by a trained neurologist. Plasma samples were available for 30 preHD (44 visits), 60 healthy controls (82 visits) and nine JoHD participants (11 total visits). Clinical severity in JoHD was assessed using the UHDRS total motor score, the JoHD Motor scale¹³ – an adapted version of UHDRS total motor score which weighs JoHD-specific components higher – and disease duration (determined by length of time from clinical diagnosis to time of study visit in years). Disease burden score (DBS) – an arithmetic composite of CAG and age that encompasses the cumulative burden of the CAG expansion [Age * (cAG-35.5)] – was used as a known predictor of HD progression¹⁴.

The preHD group was divided into subgroups based on their predicted years to motor onset (YTO) into the following groups: 40-60 YTO; 30-40 YTO; 20-30 YTO; 15-20 YTO; <15 YTO. This was calculated using the using their CAG repeat length and age in the formula from Langbehn and colleagues¹⁵.

$$YTO = Age_n - (21.54 + e^{(9.556 - [0.1460 * CAG])})$$

This formula was used only for participants with a CAG repeat length of 36-49. For participants with a CAG repeat length of 50 or above, the Langbehn formula was slightly modified to provide a more accurate estimate of the predicted years to onset. Participants were excluded from either study if they had a history of a major neurologic illness, brain surgery, or significant head trauma.

283

284 Plasma Sample Collection and Storage

285 KidsHD/JoHD blood samples were collected in EDTA Vacutainer tubes (BD). All
 286 samples were coded with a unique study ID and were sent to the University of Iowa
 287 Diagnostic Laboratories. Samples were briefly stored on ice and then centrifuged at
 288 2,000g for x minutes. Plasma was decanted before being centrifuged at 3,000g at 4°C
 289 for 15 minutes then pipetted into 1.2-mL cryotubes in 500 uL aliquots and frozen and
 290 stored at -80°C before being shipped.

291

292 NfL Quantification

293 KidsHD/JoHD plasma NfL concentrations were measured using the commercially
 294 available NF-Light® assay kit from on the Simoa HD-1 analyzer platform as per the
 295 manufacturer's instructions (Quanterix, Lexington). NfL was quantified in duplicate for all
 296 plasma samples. The intra-assay coefficient of variation (CV) was 6.5% and inter-assay
 297 CV was 1.65%. HD-CSF plasma NfL was previously quantified and published as per
 298 Rodrigues et al⁷.

299

300 Image Acquisition and processing

301 The structural imaging acquisition methods have been described previously⁹. A 3T
 302 Siemens Trio TIM (Siemens AG, Munich, Germany) machine was used to acquire
 303 images prior to June 2016 (n=33). After June 2016, a 3T General Electric Discovery
 304 MR750w (GE Medical Systems, Chicago, IL) was used (n=17). Full details regarding
 305 image processing have been previously described by van der Plas, et al⁹.

306

307 Statistical Analysis

308 In accordance with previous evaluations of plasma NfL, all available NfL concentrations
 309 underwent natural log-transformation to account for non-normal distribution^{4,6}. We
 310 assessed potentially confounding demographics and measures of healthy
 311 development on plasma NfL. None of the variables assessed had an effect on plasma
 312 NfL. However, since NfL has been shown to be associated with healthy aging, we
 313 included age as a covariate for subsequent analyses¹⁶. For the primary analyses-of-
 314 interest, we performed linear mixed effects regression (LMER) models. The accelerated
 315 longitudinal design of KidsHD/JoHD allows for modeling trajectories of development
 316 over time while statistically accounting for the correlation that occurs from repeat visits
 317 from individuals⁹. All LMER models also included random effects per family to account
 318 for siblings in the dataset. P-values were estimated using Satterthwaite approximation
 319 for degrees of freedom throughout.

320

321 For groupwise comparisons, we compared LMER model adjusted mean plasma NfL
 322 values between groups. In these models, within-subject and residual variances were
 323 estimated separately for the various groups via iteratively re-weighted least squares.
 324 This was done to account for sizable differences in variation between the groups. We
 325 adjusted for multiple comparisons using false-discovery-rate (FDR) corrections.

326

327 The age*group interaction was evaluated to determine group differences in age-
 328 trajectories of plasma NfL. To assess associations with clinical measures, LMER

models were constructed with plasma NfL as the independent variable and clinical measures as the dependent variables. LMER models for DBS – a predictor of HD progression – included NfL as the dependent variable. Age was not included as a covariate in either of the models that investigated the relationship between disease duration or DBS and plasma NfL to avoid collinearity, since age was used to calculate these variables. For neuroimaging measures, brain volumes were the dependent variables and NfL independent within the LMER models to permit the addition of scanner as a covariate to account for scanner differences. All brain volumes were presented as percent of intracranial volume (ICV).

We created a receiver operating characteristic curve by performing a generalized binomial regression model with plasma NfL as the independent predictor variable for whether or not a participant was a healthy control or had JoHD. We calculated Youden's Index by adding the sensitivity and specificity at all available plasma NfL levels. The maximal specificity cutoff point was at 0.964 and the maximal sensitivity cutoff point was at 0.909 and this point correlated with a plasma NfL cutoff point of 11.1 pg/mL. These analyses were performed using the pROC package in RStudio (version 1.16.2)

Groupwise analyses were performed using the PROC MIXED function within SAS (v9.4, SAS Institute Inc, Cary, NC, USA). All other models were performed in RStudio version 1.3.159 using the lmerTest version 3.1.

351 [Data availability](#)

352 The data that support the findings of this study are available from the corresponding
353 author upon reasonable request.

354

Supplementary material

Supplementary Table 1 Baseline Cohort Characteristics of KidsHD and KidsJoHD

P-values for continuous variables were generated from one-way analyses of variance. P-values for categorical variables were generated from Pearson Chi-Square analyses. Values are presented as mean $\pm$ SD unless otherwise stated. preHD, premanifest Huntington's disease; JoHD, Juvenile-onset Huntington's disease. SD, Standard deviation; CAG, Cytosine-Adenine-Guanine; BMI, Body mass index; SES, socioeconomic status, measured by the Hollingshead Scale; NfL, neurofilament light protein.

	Controls	preHD	JoHD	P-Value
N (total visits)	61 (83)	30 (44)	9 (11)	N/A
Age	12.75 $\pm$ 3.71	14.00 $\pm$ 3.12	16.48 $\pm$ 6.38	0.40
Males, N (%)	23 (37.7)	10 (33.3)	5 (55.6)	0.483
CAG	20.33 $\pm$ 4.39	43.90 $\pm$ 4.47	72.11 $\pm$ 12.67	<0.0001
BMI	22.14 $\pm$ 7.48	21.92 $\pm$ 5.13	21.51 $\pm$ 6.22	0.963
Tanner Stage, N (%)				0.337
0	15 (22.2)	4 (13.3)	2 (22.2)	
1	4 (6.6)	0 (0)	0 (0)	
2	4 (6.6)	1 (3.3)	0 (0)	
3	12 (19.7)	5 (16.7)	0 (0)	
4	16 (26.2)	15 (50.0)	4 (44.4)	
5	10 (16.4)	5 (16.7)	3 (33.3)	
Parental SES, N (%)				0.062
1	0 (0)	0 (0)	0 (0)	
2	36 (59.0)	14 (46.7)	2 (22.2)	
3	22 (36.1)	14 (46.7)	4 (44.4)	
4	2 (3.3)	2 (6.7)	2 (22.2)	
5	1 (1.6)	0 (0)	1 (11.1)	
Plasma NfL (pg/mL)	4.71 $\pm$ 1.55	5.05 $\pm$ 1.57	35.16 $\pm$ 2.95	<0.0001

Supplementary Table 2 Clinical measures and their associations with plasma NfL in JoHD

P-values were generated from linear mixed effects regression models with effects per participant and per family (intercepts) and using Satterthwaite approximation for degrees of freedom. Values are presented as the beta estimate of the model relative to the log-transformed plasma NfL concentration. The models that assessed the relationship between disease duration and disease burden score did not include age as a covariate, as both independent variables are calculated using age. All brain volumes were corrected for intracranial volume and models investigating the relationship between plasma NfL and brain volumes included a covariate to account for different scanners. NfL, neurofilament light protein; UHDRS, Unified Huntington's Disease Rating Scale; TMS, total motor score; JoHD, Juvenile-onset Huntington's disease.

Clinical measures	Association with plasma NfL			
	N (total visits)	Estimate	Confidence interval	P-value
UHDRS TMS	9 (11)	7.02	-13.91 – 27.94	0.522
JoHD Motor Scale	9 (11)	3.87	-0.56 – 8.30	0.119
Chorea	9 (11)	0.07	-0.57 – 0.71	0.832
Bradykinesia Handtapping	9 (11)	0.05	-0.96 – 1.05	0.934
Bradykinesia Drinking	9 (10)	1.25	0.46 – 2.05	0.017
Tremors	9 (11)	0.41	-0.38 – 1.19	0.333
Disease duration	9 (11)	1.19	0.03 – 2.35	0.045
Disease burden score	9 (11)	1.00	-0.01 – 2.01	0.347
Whole Brain Volume	9 (10)	-3.10	-7.19 – 0.99	0.180
Putamen Volume	9 (10)	-0.10	-0.20 – 0.01	0.112
Caudate Volume	9 (10)	-0.07	-0.15 – 0.01	0.116

Supplementary Table 3 Baseline Cohort Characteristics by years to onset groupings

P-values for continuous variables were generated from one-way analyses of variance. P-values for categorical variables were generated from Pearson Chi-Square analyses. Values are presented as mean ± SD unless otherwise stated. SD, Standard deviation; CAG, Cytosine-Adenine-Guanine; YTO, years to onset; BMI, Body mass index; SES, socioeconomic status, measured by the Hollingshead Scale; NfL, neurofilament light protein.

	Controls	40-60 YTO	30-40 YTO	20-30 YTO	15-20 YTO	<15 YTO	P-Value
N (total visits)	61 (83)	9 (15)	10 (12)	7 (9)	2 (4)	2 (4)	NA
Age	12.75 ± 3.71	13.99 ± 2.07	13.47 ± 3.93	13.33 ± 2.98	15.04 ± 2.65	17.96 ± 3.12	0.355
Female, N (%)	23 (37.7)	4 (44.4)	8 (80.0)	6 (85.7)	1 (50.0)	1 (50.00)	0.488
CAG	20.33 ± 4.39	39.78 ± 0.97	42.60 ± 0.84	46.71 ± 2.29	49.00 ± 1.41	54.00 ± 7.07	<0.0001
YTO	N/A	50.39 ± 6.23	36.38 ± 2.03	24.392 ± 2.87	17.96 ± 0.79	11.06 ± 1.93	<0.0001
BMI	22.14 ± 7.48	22.63 ± 5.88	20.68 ± 4.83	21.99 ± 4.86	18.23 ± 1.16	28.42 ± 1.30	0.295
Tanner Stage							0.280
0	15 (22.2)	0 (0.0)	3 (30.0)	1 (14.3)	0 (0.0)	0 (0.0)	
1	4 (6.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
2	4 (6.6)	1 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
3	12 (19.7)	4 (44.4)	0 (0.0)	0 (0.0)	1 (50.0)	0 (0.0)	
4	16 (26.2)	4 (44.4)	5 (50.0)	4 (57.1)	1 (50.0)	1 (50.0)	
5	10 (16.4)	0 (0.0)	2 (20.0)	2 (28.6)	0 (0.0)	1 (50.0)	
Parental SES, N (%)							0.366
0	0 (0)						
1	36 (59.0)	5 (55.6)	7 (70.0)	1 (14.3)	1 (50.0)	0 (0.0)	
2	22 (36.1)	3 (33.3)	3 (30.0)	5 (71.4)	1 (50.0)	2 (100.0)	
3	2 (3.3)	1 (11.1)	0 (0.0)	1 (14.3)	0 (0.0)	0 (0.0)	
4	1 (1.6)						
Plasma NfL	4.71 ± 1.55	4.81 ± 1.55	4.81 ± 1.67	4.43 ± 1.32	6.42 ± 1.48	9.97 ± 1.63	0.211

Supplementary Table 4 Plasma NfL associations with brain volume in HD mutation carriers

P-values were generated from linear mixed effects regression models with random effects per participant and per family (intercepts), age as a covariate and using Satterthwaite approximation for degrees of freedom. Values are presented as the beta estimate of the model relative to the log-transformed plasma NfL concentration. All brain volumes were corrected for intracranial volume and models investigating the relationship between plasma NfL and brain volumes included a covariate to account for different scanners. NfL, neurofilament light protein; HD, Huntington's disease; JoHD, Juvenile-onset Huntington's disease.

Clinical measures	Association with plasma NfL - All HD mutation carriers				Association with plasma NfL – JoHD and within 20 YTO			
	N (total visits)	Estimate	Confidence interval	P-value	N (total visits)	Estimate	Confidence interval	P-value
Whole Brain Volume	35 (49)	-0.90	-1.64 – -0.16	0.020	12 (17)	-1.46	-3.67 – 0.74	0.207
Caudate Volume	35 (49)	-0.06	-0.08 – -0.03	0.0001	12 (17)	-0.12	-0.18 – -0.05	0.0040
Putamen Volume	35 (49)	-0.09	-0.12 – -0.06	<0.0001	12 (17)	-0.14	-0.21 – -0.07	0.0025

